The game continues to change in biotech as continued macroeconomic uncertainty has far reaching implications for the future of the biopharma ecosystem. Biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma—and players may need to develop products further than in the past, and therefore strategic pathway optionality needs to be weaved into and maintained throughout product and corporate development. But with a multitude of new challenges facing this industry come multifold new opportunities for value creation and chances to reach new heights. In this episode, Lee Taurman, Global Head of Syneos One and Keith Ruark, SVP Strategic Business Development, Syneos Health are joined by Ali Pashazadeh and Max Baumann, Co-Founders of Treehill Partners, to discuss strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.  learn strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

The game continues to change in biotech as continued macroeconomic uncertainty has far reaching implications for the future of the biopharma ecosystem. Biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma—and players may need to develop products further than in the past, and therefore strategic pathway optionality needs to be weaved into and maintained throughout product and corporate development. But with a multitude of new challenges facing this industry come multifold new opportunities for value creation and chances to reach new heights.  In this episode, <a href="https://www.linkedin.com/search/results/all/?fetchDeterministicClustersOnly=true&amp;heroEntityKey=urn%3Ali%3Afsd_profile%3AACoAAAI6iesBO2u6sVxL3tRaVFQYM3SDOZ0or4Q&amp;keywords=lee%20taurman&amp;origin=RICH_QUERY_SUGGESTION&amp;position=0&amp;searchId=2f5f924a-b98e-4e16-8b38-d5fb9852e896&amp;sid=29h" rel="nofollow" target="_blank">Lee Taurman</a>, Global Head of Syneos One and <a href="https://www.linkedin.com/in/keith-ruark-6895a68/" rel="nofollow" target="_blank">Keith Ruark</a>, SVP Strategic Business Development, Syneos Health are joined by <a href="https://www.linkedin.com/search/results/all/?fetchDeterministicClustersOnly=true&amp;heroEntityKey=urn%3Ali%3Afsd_profile%3AACoAAAi8RbkBmIGAFGWUlYgXxDt-LeSx7IlBQ8A&amp;keywords=ali%20pashazadeh&amp;origin=RICH_QUERY_SUGGESTION&amp;position=0&amp;searchId=786bd896-85bb-48d0-8f4a-a2ac1347b00b&amp;sid=T5m" rel="nofollow" target="_blank">Ali Pashazadeh</a> and Max Baumann, Co-Founders of Treehill Partners, to discuss strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.  learn strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.  The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Biotech Value Creation

What is the healthcare industry up against in terms of recruiting, hiring, and retention, in the increasingly competitive job markets of China, Korea and Japan? Leigh Householder and Sam Wilson, commercial solutions lead for APAC, Syneos Health,  discuss how changing customer needs, evolving market dynamics and shifts in customer engagement  continue to be  challenges when recruiting top talent in the region.Learn more about 2023 Health Trends here.More Episodes in the 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor &amp; Patient Advocate, James IanTrend Talks: AI: Finally fit for PurposeTrend Talks: A New Field for the Field Force Trend Talks: The Data EffectThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

What is the healthcare industry up against in terms of recruiting, hiring, and retention, in the increasingly competitive job markets of China, Korea and Japan? <a href="https://www.linkedin.com/in/lhouseholder/" rel="nofollow" target="_blank">Leigh Householder</a> and <a href="https://www.linkedin.com/in/sam-wilson-24184729/" rel="nofollow" target="_blank">Sam Wilson</a>, commercial solutions lead for APAC, Syneos Health,  discuss how changing customer needs, evolving market dynamics and shifts in customer engagement  continue to be  challenges when recruiting top talent in the region. Learn more about 2023 Health Trends <a href="https://www.syneoshealth.com/insights-hub/2023-health-trends-personally-purposefully-building-what%E2%80%99s-next" rel="nofollow" target="_blank">here</a>. More Episodes in the 2023 Health Trends Series: <a href="https://www.syneoshealth.com/insights-hub/syneos-health-podcast-2023-health-trends-personally-purposefully-building-what%E2%80%99s-next" rel="nofollow" target="_blank">Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's Next</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-agetech-musician-actor-patient-advocate-james-ian" rel="nofollow" target="_blank">Trend Talks: AgeTech with Musician, Actor &amp; Patient Advocate, James Ian</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-ai-finally-fit-purpose" rel="nofollow" target="_blank">Trend Talks: AI: Finally fit for Purpose</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-new-field-field-force" rel="nofollow" target="_blank">Trend Talks: A New Field for the Field Force</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-ai-finally-fit-purpose" rel="nofollow" target="_blank">Trend Talks: The Data Effect</a>The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

2023 Health Trends: Improved Sophistication in Retention

In our previous episode, we covered how companies can harness the power of digital therapeutics to improve their brand’s value proposition. But what does it really take to get a clinically validated prescription digital product to market? Dr. Shaheen Lakhan, Chief Medical Officer, Click Therapeutics joins us on the second episode of our two-part series on digital therapeutics to discuss the diligence required to help regulators, health plans and payers, clinicians, and patients understand the potential of these digital solutions outside of entertainment—and how to apply the principles of traditional, biopharmaceutical types of drug development, validation and regulatory exercises to get them into the hands of patients. Listen to part one of our conversation on digital therapeutics with Austin Speier, Chief Strategy Officer of Click Therapeutics, here.  And for a deeper dive into how companies can implement DTx to expand or augment the potential of their pharmaceutical and biologic therapeutic assets, read our article 10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

In our <a href="https://www.syneoshealth.com/insights-hub/syneos-health-podcast-digital-therapeutic-commercialization" rel="nofollow" target="_blank">previous episode</a>, we covered how companies can harness the power of digital therapeutics to improve their brand’s value proposition. But what does it really take to get a clinically validated prescription digital product to market? <a href="https://www.linkedin.com/in/shaheenlakhan/" rel="nofollow" target="_blank">Dr. Shaheen Lakhan</a>, Chief Medical Officer, Click Therapeutics joins us on the second episode of our two-part series on digital therapeutics to discuss the diligence required to help regulators, health plans and payers, clinicians, and patients understand the potential of these digital solutions outside of entertainment—and how to apply the principles of traditional, biopharmaceutical types of drug development, validation and regulatory exercises to get them into the hands of patients. Listen to part one of our conversation on digital therapeutics with Austin Speier, Chief Strategy Officer of Click Therapeutics, <a href="https://www.syneoshealth.com/insights-hub/syneos-health-podcast-digital-therapeutic-commercialization" rel="nofollow" target="_blank">here</a>.  And for a deeper dive into how companies can implement DTx to expand or augment the potential of their pharmaceutical and biologic therapeutic assets, read our article <a href="https://go.syneoshealth.com/l/63102/2023-04-19/4r4jp6/63102/1681937260cHmvposc/10_Applications_of_Prescription_DTx_Across_the_Product_Lifecycle_Digita.pdf" rel="nofollow" target="_blank">10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx</a>. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Digital Therapeutic Development and Approval

Digital therapeutics (DTx) are projected to be $50 billion industry by 2025. While many minds may immediately jump to unregulated companion apps when they hear “digital,” there are also clinically validated prescription digital products that act complementary to or in combination with traditional biopharmaceutical therapies. As these prescription DTx gain traction, how can companies harness their power to improve their brand’s value proposition? In this first of two episodes on DTx, Michael Sarshad, Managing Director, Commercial Advisory at Syneos Health and Austin Speier, Chief Strategy Officer, Click Therapeutics, join the podcast to discuss the growing market and opportunities for DTx across the product lifecycle, where DTx can add value and ways to think about how to integrate them into a brand strategy. For a deeper dive into how companies can implement DTx to expand or augment the potential of their pharmaceutical and biologic therapeutic assets, read our article 10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Digital therapeutics (DTx) are projected to be $50 billion industry by 2025. While many minds may immediately jump to unregulated companion apps when they hear “digital,” there are also clinically validated prescription digital products that act complementary to or in combination with traditional biopharmaceutical therapies. As these prescription DTx gain traction, how can companies harness their power to improve their brand’s value proposition? In this first of two episodes on DTx, <a href="https://www.linkedin.com/in/michael-sarshad-9149b524/" rel="nofollow" target="_blank">Michael Sarshad</a>, Managing Director, Commercial Advisory at Syneos Health and <a href="https://www.linkedin.com/in/austinspeier/" rel="nofollow" target="_blank">Austin Speier</a>, Chief Strategy Officer, Click Therapeutics, join the podcast to discuss the growing market and opportunities for DTx across the product lifecycle, where DTx can add value and ways to think about how to integrate them into a brand strategy. For a deeper dive into how companies can implement DTx to expand or augment the potential of their pharmaceutical and biologic therapeutic assets, read our article <a href="https://go.syneoshealth.com/l/63102/2023-04-19/4r4jp6/63102/1681937260cHmvposc/10_Applications_of_Prescription_DTx_Across_the_Product_Lifecycle_Digita.pdf" rel="nofollow" target="_blank">10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx</a>.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Digital Therapeutic Commercialization

"It's July 2022. This morning I tried to donate my kidney, this afternoon the transplant team told me that I can't, I have cancer." Words no one wants to hear. Even for a former Jeopardy! champion with degrees in molecular biology and two decades of experience in the biopharma industry, the implications of the phrase are overwhelming.Nearly a year later, our flagship podcast host Jeff Stewart is telling his story.Today, Nick Kenny, Chief Scientific Officer at Syneos Health, turns the tables on Jeff, interviewing him on his recent experience being diagnosed and undergoing treatment for two separate cancers. They discuss the realities today for patients like Jeff who are dealing with complex cancer diagnoses—including information overload both fake and real, and the importance of “pre-bunking”—and his newly released book, Living: Inspiration from a Father with Cancer.At a time when regulators in our industry at large are increasingly and rightly focused on patient perspectives in drug development, and with ASCO, the single largest global gathering of about 50,000 clinical cancer experts right around the corner in early June, this is a very timely discussion.Read excerpts of the book on NPR.Check out our other content on the patient experience:Webinar: Patient Perspectives as Essential in Next-Generation Clinical TrialsExploring the Value and Impact of Patient-Reported Outcomes in Patient-Centric CAR-T Clinical Trials3 Ways Patient Voice is Impacting Rare Disease Research, According to AdvocatesThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

"It's July 2022. This morning I tried to donate my kidney, this afternoon the transplant team told me that I can't, I have cancer." Words no one wants to hear. Even for a former Jeopardy! champion with degrees in molecular biology and two decades of experience in the biopharma industry, the implications of the phrase are overwhelming.Nearly a year later, our flagship podcast host <a href="https://www.linkedin.com/in/jeff-stewart-b8783917/" rel="nofollow" target="_blank">Jeff Stewart</a> is telling his story.Today, <a href="https://www.linkedin.com/in/nickkenny/" rel="nofollow" target="_blank">Nick Kenny</a>, Chief Scientific Officer at Syneos Health, turns the tables on Jeff, interviewing him on his recent experience being diagnosed and undergoing treatment for two separate cancers. They discuss the realities today for patients like Jeff who are dealing with complex cancer diagnoses—including information overload both fake and real, and the importance of “pre-bunking”—and his newly released book, Living: Inspiration from a Father with Cancer. At a time when regulators in our industry at large are increasingly and rightly focused on patient perspectives in drug development, and with ASCO, the single largest global gathering of about 50,000 clinical cancer experts right around the corner in early June, this is a very timely discussion.Read <a href="https://www.npr.org/sections/health-shots/2023/05/19/1176952862/facing-cancer-heres-when-to-consider-experimental-therapies-and-when-not-to" rel="nofollow" target="_blank">excerpts of the book</a> on NPR. Check out our other content on the patient experience:<a href="https://www.syneoshealth.com/insights-hub/webinar-patient-perspectives-essential-next-generation-clinical-trials" rel="nofollow" target="_blank">Webinar: Patient Perspectives as Essential in Next-Generation Clinical Trials</a><a href="https://www.syneoshealth.com/insights-hub/exploring-value-and-impact-patient-reported-outcomes-patient-centric-car-t-clinical" rel="nofollow" target="_blank">Exploring the Value and Impact of Patient-Reported Outcomes in Patient-Centric CAR-T Clinical Trials</a><a href="https://www.syneoshealth.com/insights-hub/3-ways-patient-voice-impacting-rare-disease-research-according-advocates" rel="nofollow" target="_blank">3 Ways Patient Voice is Impacting Rare Disease Research, According to Advocates</a> The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Cancer: The Patient Perspective

How can we use technology and increasing volumes of data to change the future of human health and healthcare as we move forward into 2023 and beyond? In this episode of the limited Trend Talks series, Leigh Householder, Host &amp; Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Bob Zambon, VP, Solution Architecture Group, Syneos Health, to discuss how increasing numbers of varying health data − medical data, clinical data, interaction data, program data – will affect a vastly privacy forward industry.Listen to the podcast to find out how data will impact the future of healthcare.Learn more about 2023 Health Trends here.More Episodes in the 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor &amp; Patient Advocate, James IanTrend Talks: AI: Finally fit for PurposeTrend Talks: A New Field for the Field ForceFind more of our content on Digital Medicine and MedTech topics.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

How can we use technology and increasing volumes of data to change the future of human health and healthcare as we move forward into 2023 and beyond? In this episode of the limited Trend Talks series, Leigh Householder, Host &amp; Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with <a href="https://www.linkedin.com/in/razambon/" rel="nofollow" target="_blank">Bob Zambon</a>, VP, Solution Architecture Group, Syneos Health, to discuss how increasing numbers of varying health data − medical data, clinical data, interaction data, program data – will affect a vastly privacy forward industry.Listen to the podcast to find out how data will impact the future of healthcare. Learn more about 2023 Health Trends <a href="https://www.syneoshealth.com/insights-hub/2023-health-trends-personally-purposefully-building-what%E2%80%99s-next" rel="nofollow" target="_blank">here</a>. More Episodes in the 2023 Health Trends Series: <a href="https://www.syneoshealth.com/insights-hub/syneos-health-podcast-2023-health-trends-personally-purposefully-building-what%E2%80%99s-next" rel="nofollow" target="_blank">Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's Next</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-agetech-musician-actor-patient-advocate-james-ian" rel="nofollow" target="_blank">Trend Talks: AgeTech with Musician, Actor &amp; Patient Advocate, James Ian</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-ai-finally-fit-purpose" rel="nofollow" target="_blank">Trend Talks: AI: Finally fit for Purpose</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-new-field-field-force" rel="nofollow" target="_blank">Trend Talks: A New Field for the Field Force</a> Find more of our content on <a href="https://www.syneoshealth.com/insights-hub?topic=Digital%20Medicine%20+%20MedTech" rel="nofollow" target="_blank">Digital Medicine and MedTech</a> topics. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

2023 Health Trends: The Data Effect

How will a new field for the field force keep the doors open for customer communication while considering differences in culture, therapy, product lifecycle stage and healthcare professional preference?In this episode of the limited Trend Talks series, Leigh Householder, Host &amp; Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Ewan Cuthbertson, SVP, European Deployment Solutions, Syneos Health, to discuss how the field force is reemerging after a global pandemic and how it will impact the healthcare industry.Listen to the podcast to find out what a new field for the field force means for the future of healthcare.Learn more about 2023 Health Trends here.More Episodes in the 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor &amp; Patient Advocate, James IanTrend Talks: AI: Finally fit for PurposeFind more of our content on Digital Medicine and MedTech topics. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

How will a new field for the field force keep the doors open for customer communication while considering differences in culture, therapy, product lifecycle stage and healthcare professional preference?In this episode of the limited Trend Talks series, Leigh Householder, Host &amp; Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with <a href="https://www.linkedin.com/in/ewan-cuthbertson-7543a623/" rel="nofollow" target="_blank">Ewan Cuthbertson</a>, SVP, European Deployment Solutions, Syneos Health, to discuss how the field force is reemerging after a global pandemic and how it will impact the healthcare industry. Listen to the podcast to find out what a new field for the field force means for the future of healthcare. Learn more about 2023 Health Trends <a href="https://www.syneoshealth.com/insights-hub/2023-health-trends-personally-purposefully-building-what%E2%80%99s-next" rel="nofollow" target="_blank">here</a>. More Episodes in the 2023 Health Trends Series: <a href="https://www.syneoshealth.com/insights-hub/syneos-health-podcast-2023-health-trends-personally-purposefully-building-what%E2%80%99s-next" rel="nofollow" target="_blank">Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's Next</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-agetech-musician-actor-patient-advocate-james-ian" rel="nofollow" target="_blank">Trend Talks: AgeTech with Musician, Actor &amp; Patient Advocate, James Ian</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-ai-finally-fit-purpose" rel="nofollow" target="_blank">Trend Talks: AI: Finally fit for Purpose</a> Find more of our content on <a href="https://www.syneoshealth.com/insights-hub?topic=Digital%20Medicine%20+%20MedTech" rel="nofollow" target="_blank">Digital Medicine and MedTech</a> topics. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

2023 Health Trends: A New Field for the Field Force

How will Digital transformation continue to impact the healthcare industry and help drive automation, efficiencies, quality and other changes to how we engage and operate in the future?In this episode of the limited Trend Talks series, Leigh Householder, Host &amp; Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with Skye Hodson, PhD, Senior Director, Product Solutions &amp; Asset Team, Syneos One, to discuss how various aspects of digital transformation continue to impact the healthcare industry.Listen to the podcast to find out what the future holds for healthcare and digital transformation. Learn more about 2023 Health Trends here.More Episodes int he 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor &amp; Patient Advocate, James IanTrend Talks: AI: Finally fit for Purpose Find more of our content on Digital Medicine and MedTech topics.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

How will Digital transformation continue to impact the healthcare industry and help drive automation, efficiencies, quality and other changes to how we engage and operate in the future?In this episode of the limited Trend Talks series, Leigh Householder, Host &amp; Author, 2023 Health Trends: Personally, Purposefully Building What’s Next, sits down with <a href="https://www.linkedin.com/in/drskyehodson/" rel="nofollow" target="_blank">Skye Hodson</a>, PhD, Senior Director, Product Solutions &amp; Asset Team, Syneos One, to discuss how various aspects of digital transformation continue to impact the healthcare industry. Listen to the podcast to find out what the future holds for healthcare and digital transformation. Learn more about 2023 Health Trends <a href="https://www.syneoshealth.com/insights-hub/2023-health-trends-personally-purposefully-building-what%E2%80%99s-next" rel="nofollow" target="_blank">here</a>. More Episodes int he 2023 Health Trends Series: <a href="https://www.syneoshealth.com/insights-hub/syneos-health-podcast-2023-health-trends-personally-purposefully-building-what%E2%80%99s-next" rel="nofollow" target="_blank">Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's Next</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-agetech-musician-actor-patient-advocate-james-ian" rel="nofollow" target="_blank">Trend Talks: AgeTech with Musician, Actor &amp; Patient Advocate, James Ian</a> <a href="https://www.syneoshealth.com/insights-hub/trend-talks-ai-finally-fit-purpose" rel="nofollow" target="_blank">Trend Talks: AI: Finally fit for Purpose </a> Find more of our content on <a href="https://www.syneoshealth.com/insights-hub?topic=Digital%20Medicine%20+%20MedTech" rel="nofollow" target="_blank">Digital Medicine and MedTech</a> topics.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

2023 Health Trends: Digital Transformation: Start, Stall, Restart

Last year the FDA approved the first gene therapy for hemophilia B. This year, the first gene therapy may be approved in the US for hemophilia A. What does the gene therapy revolution mean for patients, payers, and pharma? Ankita Chowdhury, Senior Engagement Manager, Commercial Advisory at Syneos Health®, joins the podcast to discuss the landscape of recent hemophilia gene therapy approvals, the state of upcoming additional therapies to market, and key considerations for developers to address in order to optimize access, pricing and reimbursement for patients impacted by this rare disease. For more of our insights on rare disease and gene therapies, check out:The Importance of the Right Go-to-Market in Cell Therapy CommercializationWEBINAR: Early Integrated Evidence Strategy for Cell &amp; Gene TherapiesExploring an Expedited Regulatory Pathway for Cell and Gene TherapiesSuccess Factors for Commercializing Cell and Gene TherapiesSyneos Health Podcast: The Value of Registries NOTE: At the time of recording, Biomarin’s hemophilia A product was expected to receive FDA approval in March of this year. Since then, news broke that FDA review will be delayed until June.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Last year the FDA approved the <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b" rel="nofollow" target="_blank">first gene therapy for hemophilia B</a>. This year, the first gene therapy may be approved in the US for hemophilia A. What does the gene therapy revolution mean for patients, payers, and pharma? <a href="https://www.linkedin.com/in/ankita-chowdhury/" rel="nofollow" target="_blank">Ankita Chowdhury</a>, Senior Engagement Manager, Commercial Advisory at Syneos Health®, joins the podcast to discuss the landscape of recent hemophilia gene therapy approvals, the state of upcoming additional therapies to market, and key considerations for developers to address in order to optimize access, pricing and reimbursement for patients impacted by this rare disease. For more of our insights on rare disease and gene therapies, check out:<a href="https://www.syneoshealth.com/insights-hub/importance-right-go-market-strategy-cell-therapy-commercialization" rel="nofollow" target="_blank">The Importance of the Right Go-to-Market in Cell Therapy Commercialization</a><a href="https://www.syneoshealth.com/insights-hub/webinar-importance-early-integrated-evidence-strategy-cell-gene-therapies" rel="nofollow" target="_blank">WEBINAR: Early Integrated Evidence Strategy for Cell &amp; Gene Therapies</a><a href="https://www.syneoshealth.com/insights-hub/exploring-expedited-regulatory-pathway-cell-and-gene-therapies" rel="nofollow" target="_blank">Exploring an Expedited Regulatory Pathway for Cell and Gene Therapies</a><a href="https://www.syneoshealth.com/insights-hub/success-factors-commercializing-cell-and-gene-therapies" rel="nofollow" target="_blank">Success Factors for Commercializing Cell and Gene Therapies</a><a href="https://www.syneoshealth.com/insights-hub/syneos-health-podcast-value-registries" rel="nofollow" target="_blank">Syneos Health Podcast: The Value of Registries</a> NOTE: At the time of recording, Biomarin’s hemophilia A product was expected to receive FDA approval in March of this year. Since then, news broke that FDA review will be <a href="https://endpts.com/fda-delays-review-of-biomarins-hemophilia-gene-therapy-after-data-update/" rel="nofollow" target="_blank">delayed until June</a>.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Gene Therapy for Hemophilia

The Inflation Reduction Act of 2022 is a landmark United States federal law which aims to curb inflation by, among other things, lowering prescription drug prices. What can this mean for biopharmaceutical companies?Dennis Kim, Senior Engagement Manager and Em Coriale, Director in the Value &amp; Access team at Syneos Health, dive into the details of this piece of legislation, the true meaning of “unjustified price increases,” what negotiation might look like and how companies can prepare for the new reality.   For additional insights on the Inflation Reduction Act from our Reputation &amp; Risk Management team, visit our blog.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

The <a href="https://www.congress.gov/bill/117th-congress/house-bill/5376/text" rel="nofollow" target="_blank">Inflation Reduction Act of 2022</a> is a landmark United States federal law which aims to curb inflation by, among other things, lowering prescription drug prices. What can this mean for biopharmaceutical companies? Dennis Kim, Senior Engagement Manager and <a href="https://www.linkedin.com/in/emily-coriale-pharmd-230a7019/" rel="nofollow" target="_blank">Em Coriale</a>, Director in the Value &amp; Access team at Syneos Health, dive into the details of this piece of legislation, the true meaning of “unjustified price increases,” what negotiation might look like and how companies can prepare for the new reality.    For additional insights on the Inflation Reduction Act from our Reputation &amp; Risk Management team, visit our <a href="https://www.syneoshealth.com/insights-hub/next-steps-life-sciences-industry-after-inflation-reduction-act-ira" rel="nofollow" target="_blank">blog</a>. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

The Inflation Reduction Act

The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today.  Our clinical and commercial experts provide  time-tested solutions, as well as perspectives on the news of the day.  Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.

The Syneos Health Podcast

The power of the payer in the biopharmaceutical industry has increased dramatically over the past several years, according to Keith Kelly, Managing Director and Head of the Pricing and Market Access Practice of inVentiv Health Consulting.  Market access was once a dull topic. Today, price and if a drug will be covered is discussed on earnings calls and in the board room. What payers do can make or break the stock price of a company overnight.  In this episode, Kelly and host Jeff Stewart discuss what factors have contributed to the payer’s rise in influence; how payers are wielding this power; why drug price negotiation is similar to discount suit shopping; and the “prisoner’s dilemma” of acquiring access for products entering the market at the same or similar time.  The pair also explores the nirvana concept of “sustainable market access” – is it even possible? – and the value creation equation for a pharmaceutical company looking to achieve it for their products.  Data from this episode originated from the following sources: Gross to net pricing from Credit Suisse; manufacturing cost analysis published in the Journal of Pharmaceutical Innovation and Nature Biotechnology; and Hepatitic C drug costs covered in  Reuters.  The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.  The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you.  inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.   The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health’s clients, customers or other contacts.  The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

The power of the payer in the biopharmaceutical industry has increased dramatically over the past several years, according to Keith Kelly, Managing Director and Head of the Pricing and Market Access Practice of <a href="http://consulting.inventivhealth.com" rel="nofollow" target="_blank">inVentiv Health Consulting</a>. Market access was once a dull topic. Today, price and if a drug will be covered is discussed on earnings calls and in the board room. What payers do can make or break the stock price of a company overnight. In this episode, Kelly and host Jeff Stewart discuss what factors have contributed to the payer’s rise in influence; how payers are wielding this power; why drug price negotiation is similar to discount suit shopping; and the “prisoner’s dilemma” of acquiring access for products entering the market at the same or similar time. The pair also explores the nirvana concept of “sustainable market access” – is it even possible? – and the value creation equation for a pharmaceutical company looking to achieve it for their products. Data from this episode originated from the following sources: Gross to net pricing from <a href="https://doc.research-and-analytics.csfb.com/docView?language=ENG&amp;format=PDF&amp;source_id=csplusresearchcp&amp;document_id=1047911451&amp;serialid=hfXhzuK6sK6xRrBsMZzLqZ96QTl7v2YM0kkwWJRGRVU=" rel="nofollow" target="_blank">Credit Suisse</a>; manufacturing cost analysis published in the <a href="https://www.researchgate.net/publication/225466494_Analysis_of_Manufacturing_Costs_in_Pharmaceutical_Companies" rel="nofollow" target="_blank">Journal of Pharmaceutical Innovation</a> and <a href="http://www.nature.com/nbt/journal/v19/n9/full/nbt0901-813.html" rel="nofollow" target="_blank">Nature Biotechnology</a>; and Hepatitic C drug costs covered in <a href="http://www.reuters.com/article/us-health-hepatitisc-costs-idUSKBN0MC2CK20150316" rel="nofollow" target="_blank"> Reuters</a>. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health’s clients, customers or other contacts. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 003: Payer Power

The COVID-19 (coronavirus) outbreak continues to grow worldwide – recently declared by the World Health Organization as a global pandemic – with widespread personal, medical, and business implications. In this first episode of our Coronavirus Special Edition Series, we hear the personal experience of Dr. Siying Zou, a cell biologist on the Syneos Health Consulting team in the United States. Dr. Zou is from Wuhan, China – the epicenter of the COVID-19 outbreak – and her mother and other family members have been diagnosed with the disease. This is her family’s story from the front lines, from lockdown, to hospitalization, to hope.Stay tuned for more installments of the Coronavirus Special Edition Series, which will explore, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&amp;D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.  * This episode was recorded on 3/11/2020.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

The COVID-19 (coronavirus) outbreak continues to grow worldwide – recently declared by the World Health Organization as a global pandemic – with widespread personal, medical, and business implications. In this first episode of our Coronavirus Special Edition Series, we hear the personal experience of Dr. Siying Zou, a cell biologist on the Syneos Health Consulting team in the United States. Dr. Zou is from Wuhan, China – the epicenter of the COVID-19 outbreak – and her mother and other family members have been diagnosed with the disease. This is her family’s story from the front lines, from lockdown, to hospitalization, to hope.Stay tuned for more installments of the Coronavirus Special Edition Series, which will explore, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&amp;D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our <a href="https://www.syneoshealth.com/covid-19-resource-center" rel="nofollow" target="_blank">COVID-19 Resource Center</a>.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at <a href="http://www.insightshub.health" rel="nofollow" target="_blank">insightshub.health</a>.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.  * This episode was recorded on 3/11/2020.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

CORONAVIRUS SPECIAL EDITION, Episode 1: The Personal Experience

What’s in a name? Quite a lot, actually, despite what Shakespeare says. When it comes to a merger, this can be even more important.  With research showing that up to 80% of mergers fail – and one major reason being clashing corporate cultures during post-merger integration – choosing a name and brand that the entire organization can get behind is critical to success. In this episode, listen to Kristen Spensieri of Syneos Health and Joe Daley of Syneos Health branding firm Addison Whitney discuss how the company is walking the talk – rebranding its own organization after the 2017 merger of INC Research and inVentiv Health, and how these principles can be applied to any company going through a rebrand. Listen to Part 2 of our Naming series here. See our full list of podcast episodes here.   The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actioThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

What’s in a name? Quite a lot, actually, despite what Shakespeare says. When it comes to a merger, this can be even more important.  <a href="http://knowledge.wharton.upenn.edu/article/why-do-so-many-mergers-fail/" rel="nofollow" target="_blank">With research showing</a> that up to 80% of mergers fail – and one major reason being clashing corporate cultures during post-merger integration – choosing a name and brand that the entire organization can get behind is critical to success. In this episode, listen to <a href="https://www.linkedin.com/in/kristen-spensieri-b0237819/" rel="nofollow" target="_blank">Kristen Spensieri</a> of Syneos Health and <a href="https://www.linkedin.com/in/joseph-daley-4535698/" rel="nofollow" target="_blank">Joe Daley</a> of Syneos Health branding firm Addison Whitney discuss how the company is walking the talk – rebranding its own organization after the 2017 merger of INC Research and inVentiv Health, and how these principles can be applied to any company going through a rebrand. Listen to Part 2 of our Naming series <a href="http://www.buzzsprout.com/85116/621183-episode-011-naming-part-2-the-drug" rel="nofollow" target="_blank">here</a>. See our full list of podcast episodes <a href="http://www.buzzsprout.com/85116" rel="nofollow" target="_blank">here</a>. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actioThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 010: Naming, Part 1 - The Pharma Company

As we head toward the close of the year, we are already looking to see what 2019 has in store.  Drawing on the knowledge and experience of more than 200 leaders and experts who work on the front lines of healthcare, we identified 10 critical shifts that will change how we test and commercialize novel new therapies and innovations in the years ahead.In this first of two episodes on the Health Trend Ten, Leigh Householder,  EVP / Managing Director, Insights and Innovation, and Bryan Distefano, EVP, Sales, Selling Solutions at Syneos Health, discuss key commercial trends that will impact the industry going into 2019 – including the precarious state of the healthcare practitioner, a rewiring of launch (and how we invest), the sales force of the future, and the potential (inevitable?) shift of the “M” in CMO.  Listen to part two of our Health Trend Ten series – the clinical perspective – here. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you.Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

As we head toward the close of the year, we are already looking to see what 2019 has in store.  Drawing on the knowledge and experience of more than 200 leaders and experts who work on the front lines of healthcare, we identified 10 critical shifts that will change how we test and commercialize novel new therapies and innovations in the years ahead.In this first of two episodes on the <a href="http://www.trends.health" rel="nofollow" target="_blank">Health Trend Ten</a>, <a href="https://www.linkedin.com/in/lhouseholder/" rel="nofollow" target="_blank">Leigh Householder</a>,  EVP / Managing Director, Insights and Innovation, and <a href="https://www.linkedin.com/in/bryandistefano/" rel="nofollow" target="_blank">Bryan Distefano</a>, EVP, Sales, Selling Solutions at Syneos Health, discuss key commercial trends that will impact the industry going into 2019 – including the precarious state of the healthcare practitioner, a rewiring of launch (and <a href="https://invivo.pharmaintelligence.informa.com/IV005327/TO-SPEND-OR-NOT-TO-SPEND-Investing-For-Launch-Success-As-An-Emerging-Company" rel="nofollow" target="_blank">how we invest</a>), the sales force of the future, and the potential (inevitable?) shift of the “M” in CMO.  Listen to part two of our Health Trend Ten series – the clinical perspective – <a href="http://www.buzzsprout.com/85116/871417-episode-026-the-health-trend-ten-clinical-perspective" rel="nofollow" target="_blank">here</a>. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you.Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 025: The Health Trend Ten - Commercial Perspective

In Episode 012: Medical Affairs from Zero, Suma Ramadas talked about the inception and growing value of the Medical Affairs function. Today, in part two of our Medical Affairs Transformation series, Suma is joined by Susan Suponcic, Managing Director and head of the Pricing &amp; Market Access practice of Syneos Health Consulting to discuss the importance of collaboration between the Medical Affairs and Market Access functions in developing a consistent and clear medical narrative. For a deeper dive into maximizing the impact of Medical Affairs through strategic alignment and collaboration, check out our white paper and recent Pharmaceutical Executive webinar. Would you like to add to the discussion? Write to us at podcast@syneoshealth.com.  See our full list of podcast episodes here. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.  The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

In <a href="http://www.buzzsprout.com/85116/638281-episode-012-medical-affairs-from-zero" rel="nofollow" target="_blank">Episode 012: Medical Affairs from Zero</a>, Suma Ramadas talked about the inception and growing value of the Medical Affairs function. Today, in part two of our Medical Affairs Transformation series, Suma is joined by <a href="https://www.linkedin.com/in/susan-suponcic-b7246719/" rel="nofollow" target="_blank">Susan Suponcic</a>, Managing Director and head of the Pricing &amp; Market Access practice of <a href="https://www.syneoshealth.com/solutions/consulting" rel="nofollow" target="_blank">Syneos Health Consulting</a> to discuss the importance of collaboration between the Medical Affairs and Market Access functions in developing a consistent and clear medical narrative. For a deeper dive into maximizing the impact of Medical Affairs through strategic alignment and collaboration, check out our <a href="https://www.syneoshealth.com/perspectives/new-role-medical-affairs-defining-and-driving-product-success" rel="nofollow" target="_blank">white paper</a> and recent <a href="https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;partnerref=UBMWEB&amp;eventid=1565905&amp;sessionid=1&amp;key=13A980D607E6A4C72ED60550D80BE4B9&amp;regTag=&amp;sourcepage=register" rel="nofollow" target="_blank">Pharmaceutical Executive webinar</a>. Would you like to add to the discussion? Write to us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>. See our full list of podcast episodes <a href="http://www.buzzsprout.com/85116" rel="nofollow" target="_blank">here</a>. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 014: MA-"Squared": Medical Affairs Meets Market Access

As we head toward the close of the year, we are already looking to see what 2019 has in store.  Drawing on the knowledge and experience of more than 200 leaders and experts who work on the front lines of healthcare, we identified 10 critical shifts that will change how we test and commercialize novel new therapies and innovations in the years ahead.  In our last episode, we heard about some of the commercial insights from the Health Trend Ten. Today, Leigh Householder,  EVP / Managing Director, Insights and Innovation, and Nick Kenny, Chief Scientific Officer at Syneos Health, discuss key clinical trends that will impact the industry going into 2019 – including the “trials everywhere” model, the power of digital innovation, China’s disruptive impact and the penultimate importance of data.   Listen to part one of our Health Trend Ten series – the commercial perspective – here. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you.Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.  The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

As we head toward the close of the year, we are already looking to see what 2019 has in store.  Drawing on the knowledge and experience of more than 200 leaders and experts who work on the front lines of healthcare, we identified 10 critical shifts that will change how we test and commercialize novel new therapies and innovations in the years ahead.  In our last episode, we heard about some of the commercial insights from the <a href="http://www.trends.health" rel="nofollow" target="_blank">Health Trend Ten</a>. Today, <a href="https://www.linkedin.com/in/lhouseholder/" rel="nofollow" target="_blank">Leigh Householder</a>,  EVP / Managing Director, Insights and Innovation, and <a href="https://www.linkedin.com/in/nickkenny/" rel="nofollow" target="_blank">Nick Kenny</a>, Chief Scientific Officer at Syneos Health, discuss key clinical trends that will impact the industry going into 2019 – including the “trials everywhere” model, the power of digital innovation, China’s disruptive impact and the penultimate importance of data.   Listen to part one of our Health Trend Ten series – the commercial perspective – <a href="http://www.buzzsprout.com/85116 /871204-episode-025-the-health-trend-ten-commercial-perspective" rel="nofollow" target="_blank">here</a>. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you.Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.  The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 026: The Health Trend Ten - Clinical Perspective

When it comes to investing in the launch of your biopharma product, how much is too much?  Is there such a thing as too little? Director Sachin Purwar and his colleagues from the Commercial Strategy &amp; Planning practice of Syneos Health Consulting set out to answer these questions - and found the "sweet spot" for launch spending that could mean the difference between success and failure. The team's review of 19 emerging biopharma company launches was recently published in IN VIVO. In this episode, Sachin discusses with host Jeff Stewart special considerations, pitfalls to avoid, and the implications of spend on the potential for a new product to fly - or flop - in its first year out of the gate. See our full list of podcast episodes here. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.  The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

When it comes to investing in the launch of your biopharma product, how much is too much?  Is there such a thing as too little? Director <a href="https://www.linkedin.com/in/sachin-purwar-a5267b6/" rel="nofollow" target="_blank">Sachin Purwar</a> and his colleagues from the Commercial Strategy &amp; Planning practice of <a href="https://www.syneoshealth.com/solutions/consulting" rel="nofollow" target="_blank">Syneos Health Consulting</a> set out to answer these questions - and found the "sweet spot" for launch spending that could mean the difference between success and failure. The team's review of 19 emerging biopharma company launches was recently published in <a href="https://invivo.pharmaintelligence.informa.com/IV005327/TO-SPEND-OR-NOT-TO-SPEND-Investing-For-Launch-Success-As-An-Emerging-Company" rel="nofollow" target="_blank">IN VIVO</a>. In this episode, Sachin discusses with host Jeff Stewart special considerations, pitfalls to avoid, and the implications of spend on the potential for a new product to fly - or flop - in its first year out of the gate. See our full list of podcast episodes <a href="http://www.buzzsprout.com/85116" rel="nofollow" target="_blank">here</a>. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 022: Spending for Launch Success

Clinical trials are arguably the largest investment a biopharma company makes in bringing a product to market - in dollars, and time. Driving the stakes higher: the patient is waiting. How can we improve the process, realize shorter and more efficient trials, and ultimately get the therapy to that patient faster?  Syneos Health Clinical Solutions experts Kellie Malloy, Executive Vice President and General Manager and Eleanore Doyle, Senior Vice President, Strategic Resourcing, share their thoughts on the current state of and future opportunities for clinical trials – including the impact and potential of technology, improvements in recruitment and enrollment… and keeping the human element in mind throughout. See our full list of podcast episodes here. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.  The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Clinical trials are arguably the largest investment a biopharma company makes in bringing a product to market - in dollars, and time. Driving the stakes higher: the patient is waiting. How can we improve the process, realize shorter and more efficient trials, and ultimately get the therapy to that patient faster? <a href="https://www.syneoshealth.com/solutions/clinical-development" rel="nofollow" target="_blank">Syneos Health Clinical Solutions</a> experts <a href="https://www.linkedin.com/in/kellie-malloy-foerter-1105397/" rel="nofollow" target="_blank">Kellie Malloy</a>, Executive Vice President and General Manager and <a href="https://www.linkedin.com/in/eleanore-doyle/" rel="nofollow" target="_blank">Eleanore Doyle</a>, Senior Vice President, Strategic Resourcing, share their thoughts on the current state of and future opportunities for clinical trials – including the impact and potential of technology, improvements in recruitment and enrollment… and keeping the human element in mind throughout. See our full list of podcast episodes <a href="http://www.buzzsprout.com/85116" rel="nofollow" target="_blank">here</a>. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 023: The Clinical Trial Marathon, at a Sprint

Imagine two products that are very similar. One became one of the most successful launches the organization ever had; the other one was a flop. The main difference between the two? Medical Affairs. There was a time - not all that long ago - when the Medical Affairs function did not exist. Today, the Medical Affairs organization is critical to a successful product launch, providing foresight into understanding who all of the stakeholders are and all of their evidentiary needs: getting the right evidence at the right time, communicated in the right way, to the right audience. Suma Ramadas, Managing Director in the Medical Practice Area at Syneos Health Consulting, discusses with host Jeff Stewart the inception of what we know today as Medical Affairs, its evolution to current state - and what needs to happen now in order for Medical Affairs to transform into the powerhouse function of tomorrow. For a deeper dive into maximizing the impact of Medical Affairs through strategic alignment and collaboration, check out our Pharmaceutical Executive webinar See our full list of podcast episodes here. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.  The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Imagine two products that are very similar. One became one of the most successful launches the organization ever had; the other one was a flop. The main difference between the two? Medical Affairs. There was a time - not all that long ago - when the Medical Affairs function did not exist. Today, the Medical Affairs organization is critical to a successful product launch, providing foresight into understanding who all of the stakeholders are and all of their evidentiary needs: getting the right evidence at the right time, communicated in the right way, to the right audience. <a href="https://www.linkedin.com/in/suma-ramadas-56314518/" rel="nofollow" target="_blank">Suma Ramadas</a>, Managing Director in the Medical Practice Area at <a href="http://www.syneoshealth.com/solutions/consulting" rel="nofollow" target="_blank">Syneos Health Consulting</a>, discusses with host Jeff Stewart the inception of what we know today as Medical Affairs, its evolution to current state - and what needs to happen now in order for Medical Affairs to transform into the powerhouse function of tomorrow. For a deeper dive into maximizing the impact of Medical Affairs through strategic alignment and collaboration, check out our <a href="https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;partnerref=UBMWEB&amp;eventid=1565905&amp;sessionid=1&amp;key=13A980D607E6A4C72ED60550D80BE4B9&amp;regTag=&amp;sourcepage=register" rel="nofollow" target="_blank">Pharmaceutical Executive webinar</a> See our full list of podcast episodes <a href="http://www.buzzsprout.com/85116" rel="nofollow" target="_blank">here.</a> The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 012: Medical Affairs from Zero

The treatment of cancer has undergone a sea change in the span of a generation.  In this two-part episode for World Cancer Day, we discuss the increasingly complex oncology landscape, from both a clinical and clinician perspective.  First, Bob Millham, Executive Vice President of Clinical Development and head of our Oncology Center of Excellence, addresses the potential of clinical research in driving toward a world where cancer is treated more like a chronic condition than a death sentence – and the ongoing, critical importance of engaging patients in the process.We then hear from Dave Querry, President of The Navicor Group, on the evolving role of the oncologist and how manufacturers need to think about engaging differently with this increasingly specialized practitioner.Interested in reading more?  Follow these links for a deeper dive into a broad range of oncology topics from these and other Syneos Health experts:Trends In Oncology Trial Terminations Due To Toxicity ESMO 2018 Congress: Some Good Answers and Quite a Few New Questions Pursuing Accelerated Approval in Oncology IndicationsThe Importance of Real World Evidence in OncologyBIO18: Oncology Surplus Could Drive Down ValuesA New Reality for Small Oncology Trial Sites: A Need to Adopt a Federated Approach?The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

The treatment of cancer has undergone a sea change in the span of a generation.  In this two-part episode for <a href="https://www.worldcancerday.org/" rel="nofollow" target="_blank">World Cancer Day</a>, we discuss the increasingly complex oncology landscape, from both a clinical and clinician perspective.  First, <a href="https://www.linkedin.com/in/robert-millham-87915511/" rel="nofollow" target="_blank">Bob Millham</a>, Executive Vice President of <a href="https://www.linkedin.com/company/syneoshealthclinicalsolutions/" rel="nofollow" target="_blank">Clinical Development</a> and head of our Oncology Center of Excellence, addresses the potential of clinical research in driving toward a world where cancer is treated more like a chronic condition than a death sentence – and the ongoing, critical importance of engaging patients in the process.We then hear from <a href="https://www.linkedin.com/in/dave-querry-7bb5712/" rel="nofollow" target="_blank">Dave Querry</a>, President of <a href="https://www.linkedin.com/company/the-navicor-group/" rel="nofollow" target="_blank">The Navicor Group</a>, on the evolving role of the oncologist and how manufacturers need to think about engaging differently with this increasingly specialized practitioner.Interested in reading more?  Follow these links for a deeper dive into a broad range of oncology topics from these and other Syneos Health experts:<a href="https://www.clinicalleader.com/doc/trends-in-oncology-trial-terminations-due-to-toxicity-0001?vm_isPreview=true&amp;user=03116A47-177B-49F7-B84F-0A85DD4BA47D&amp;utm_source=et_6212879&amp;utm_medium=email&amp;utm_campaign=CLNCL_06-06-2018&amp;utm_term=03116A47-177B-49F7-B84F-0A85DD4BA47D&amp;utm_content=Trends+In+Oncology+Trial+Terminations+Due+To+Toxicity%253a+A+Focus+On+Studies+In+Elderly+Populations#_ftn1" rel="nofollow" target="_blank">Trends In Oncology Trial Terminations Due To Toxicity</a> <a href="https://www.syneoshealth.com/news/ESMO-2018-Congress-Some-Good-Answers-and-Quite-a-Few-New-Questions" rel="nofollow" target="_blank">ESMO 2018 Congress: Some Good Answers and Quite a Few New Questions</a> <a href="https://www.syneoshealth.com/perspectives/pursuing-accelerated-approval-oncology-indications" rel="nofollow" target="_blank">Pursuing Accelerated Approval in Oncology Indications</a><a href="https://www.clinicalleader.com/doc/the-importance-of-real-world-evidence-in-oncology-0001" rel="nofollow" target="_blank">The Importance of Real World Evidence in Oncology</a><a href="https://www.biopharmadive.com/news/bio18-oncology-surplus-could-drive-down-values/524801/" rel="nofollow" target="_blank">BIO18: Oncology Surplus Could Drive Down Values</a><a href="https://www.linkedin.com/feed/update/urn:li:activity:6491892171589902336/" rel="nofollow" target="_blank">A New Reality for Small Oncology Trial Sites: A Need to Adopt a Federated Approach?</a>The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 028: World Cancer Day

It’s just one word.  But it carries the weight of over 43 million people, about a quarter which spends 41 hours or more per week providing care for loved ones with medical conditions.  Caregivers are not just influencers for healthcare decision-making; many are the decision makers, according to Carolyn Stephenson, SVP, Director of Insights, and Ilya Vedrashko, Managing Director, Communications Research at Syneos Health.  Together, they’ll tease out key findings from their recent survey of over 1,000 caregivers to truly understand these individuals and what lies beneath the surface in their experiences and perception.The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you.Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

It’s just one word.  But it carries the weight of over 43 million people, about a quarter which spends 41 hours or more per week providing care for loved ones with medical conditions.  Caregivers are not just influencers for healthcare decision-making; many are the decision makers, according to <a href="https://www.linkedin.com/in/carolynkent/" rel="nofollow" target="_blank">Carolyn Stephenson</a>, SVP, Director of Insights, and <a href="https://www.linkedin.com/in/vedrashko/" rel="nofollow" target="_blank">Ilya Vedrashko</a>, Managing Director, Communications Research at Syneos Health.  Together, they’ll tease out key findings from their recent <a href="https://syneoshealthcommunications.com/perspectives/whos-really-at-the-center-what-we-can-learn-from-caregiversthe-missing-link-to-patient-centricity" rel="nofollow" target="_blank">survey of over 1,000 caregivers</a> to truly understand these individuals and what lies beneath the surface in their experiences and perception.The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you.Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 027: Caregivers

The last decade has seen both depressing lows and astounding highs in biopharmaceutical dealmaking activity. Different therapeutic areas have fallen in and out of favor along with the pace of innovation and there has been a sustained focus on the next "hot spot" with high commercial value and the potential to provide solid returns for stakeholders. But certain trends have been persistent. What has changed? What has remained the same? Neel Patel, Managing Director and Sachin Purwar, Director at Syneos Health Consulting discuss the last ten years of dealmaking and take a look forward based on the results of our 10th annual Dealmakers' Intentions Study - a report that takes the pulse of pharmaceutical executives around their expectations for licensing and acquisitions in the upcoming year. See our full list of podcast episodes here. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.  The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

The last decade has seen both depressing lows and astounding highs in biopharmaceutical dealmaking activity. Different therapeutic areas have fallen in and out of favor along with the pace of innovation and there has been a sustained focus on the next "hot spot" with high commercial value and the potential to provide solid returns for stakeholders. But certain trends have been persistent. What has changed? What has remained the same? <a href="https://www.linkedin.com/in/neelpz/" rel="nofollow" target="_blank">Neel Patel</a>, Managing Director and <a href="https://www.linkedin.com/in/sachin-purwar-a5267b6/" rel="nofollow" target="_blank">Sachin Purwar</a>, Director at <a href="http://www.syneoshealth.com/solutions/consulting" rel="nofollow" target="_blank">Syneos Health Consulting</a> discuss the last ten years of dealmaking and take a look forward based on the results of our <a href="http://www.syneoshealth.com/dealmakers2018" rel="nofollow" target="_blank">10th annual Dealmakers' Intentions Study</a> - a report that takes the pulse of pharmaceutical executives around their expectations for licensing and acquisitions in the upcoming year. See our full list of podcast episodes <a href="http://www.buzzsprout.com/85116" rel="nofollow" target="_blank">here</a>. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 019: A Decade of Dealmakers' Intentions

Research in the area of live biotherapeutics has exploded in the last seven years. There is still much to learn about whether a dysregulated gut microbiome (dysbiosis) causes disease, or whether disease leads to dysbiosis – but the potential for significant contribution to healthcare is there. Erin Mistry, Senior Managing Director, and Thunicia Moodley, Senior Engagement Manager for Syneos Health Consulting, talk about the prospects for microbiome research, implications for future medical care, and the challenges inherent in bringing a new therapeutic area to the forefront.For a deeper dive, check out our new white paper here.  Like what you’re hearing?  Subscribe, rate and review us!The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Research in the area of live biotherapeutics has exploded in the last seven years. There is still much to learn about whether a dysregulated gut microbiome (dysbiosis) causes disease, or whether disease leads to dysbiosis – but the potential for significant contribution to healthcare is there. <a href="https://www.linkedin.com/in/erin-mistry-b1283832/" rel="nofollow" target="_blank">Erin Mistry</a>, Senior Managing Director, and <a href="https://www.linkedin.com/in/thunicia-moodley-0897a911/" rel="nofollow" target="_blank">Thunicia Moodley</a>, Senior Engagement Manager for <a href="https://www.syneoshealth.com/solutions/consulting" rel="nofollow" target="_blank">Syneos Health Consulting</a>, talk about the prospects for microbiome research, implications for future medical care, and the challenges inherent in bringing a new therapeutic area to the forefront.For a deeper dive, check out our new white paper <a href="https://www.syneoshealth.com/perspectives/can-gut-microbiome-revolutionize-medical-care" rel="nofollow" target="_blank">here</a>.  Like what you’re hearing?  Subscribe, rate and review us!The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 034: Can the Gut Microbiome Revolutionize Medical Care?

As we’ve hammered home over the last several episodes of this series, Medical Affairs can bring great value to any moment in an asset’s life cycle.  But there is one area where developers may be missing out on an opportunity to gain real traction in their efforts.Today we dive deeper into a Medical Affairs sweet spot with Steve Gomez, Senior Engagement Manager on the Scientific and Medical Affairs team at Syneos Health Consulting, discussing the ways that today’s Medical Affairs organization can be a shepherd, strategic partner, and even the leader for an organization in the earliest stages of development.For more episodes on Medical Affairs:Medical Affairs from ZeroMA “Squared”: Medical Affairs Meets Market AccessMedical Affairs Series, Part One – A Foundation for Medical AffairsMedical Affairs Series, Part Two – Measuring the Unmeasurable: Medical Affairs MetricsMedical Affairs Series, Part Three – Moving to the LeftMedical Affairs Series, Part Four – Medical Affairs in the FieldIf you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

As we’ve hammered home over the last several episodes of this series, Medical Affairs can bring great value to any moment in an asset’s life cycle.  But there is one area where developers may be missing out on an opportunity to gain real traction in their efforts.Today we dive deeper into a Medical Affairs sweet spot with <a href="https://www.linkedin.com/in/steven-gomez-5b37821b/" rel="nofollow" target="_blank">Steve Gomez</a>, Senior Engagement Manager on the Scientific and Medical Affairs team at Syneos Health Consulting, discussing the ways that today’s Medical Affairs organization can be a shepherd, strategic partner, and even the leader for an organization in the earliest stages of development.For more episodes on Medical Affairs:<a href="http://www.buzzsprout.com/85116/638281-episode-012-medical-affairs-from-zero" rel="nofollow" target="_blank">Medical Affairs from Zero</a><a href="http://www.buzzsprout.com/85116/656811-episode-014-ma-squared-medical-affairs-meets-market-access" rel="nofollow" target="_blank">MA “Squared”: Medical Affairs Meets Market Access</a><a href="http://www.buzzsprout.com/85116/1686946-medical-affairs-series-part-one-a-foundation-for-medical-affairs" rel="nofollow" target="_blank">Medical Affairs Series, Part One – A Foundation for Medical Affairs</a><a href="http://www.buzzsprout.com/85116/1835794-medical-affairs-series-part-two-measuring-the-unmeasurable-medical-affairs-metrics" rel="nofollow" target="_blank">Medical Affairs Series, Part Two – Measuring the Unmeasurable: Medical Affairs Metrics</a><a href="http://www.buzzsprout.com/85116/2002954-medical-affairs-series-part-three-moving-to-the-left" rel="nofollow" target="_blank">Medical Affairs Series, Part Three – Moving to the Left</a><a href="http://www.buzzsprout.com/85116/2117655-medical-affairs-series-part-four-medical-affairs-in-the-field" rel="nofollow" target="_blank">Medical Affairs Series, Part Four – Medical Affairs in the Field</a>If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at <a href="http://www.insightshub.health" rel="nofollow" target="_blank">insightshub.health</a>.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Medical Affairs Series, Part Five: Medical Affairs in the Early Stage

FDA approval is no longer the finish line in the race to product launch success. Access and adoption have risen to the forefront as a major post-approval hurdle: recent research from Syneos Health Consulting’s Value and Access team shows that less than half of newly approved drugs appeared on formulary in their launch year. So what’s a drug developer to do?Co-authors of the report on insurance coverage of new drugs at launch Jeff Stewart, Brian Cotten and Heather Martin discuss the results of their analysis, what developers can expect from payers in launch year, and how they can prepare the best possible access outcome for their new drug.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

FDA approval is no longer the finish line in the race to product launch success. Access and adoption have risen to the forefront as a major post-approval hurdle: recent research from Syneos Health Consulting’s Value and Access team shows that less than half of newly approved drugs appeared on formulary in their launch year. So what’s a drug developer to do?Co-authors of the <a href="https://www.syneoshealth.com/insights-hub/syneos-health-podcast-denials-delays-and-deep-discounts-pharmaceutical-launch" rel="nofollow" target="_blank">report on insurance coverage of new drugs at launch</a> <a href="https://www.linkedin.com/in/jeff-stewart-b8783917/" rel="nofollow" target="_blank">Jeff Stewart</a>, <a href="https://www.linkedin.com/in/brian-cotten-8a2ba0164/" rel="nofollow" target="_blank">Brian Cotten</a> and <a href="https://www.linkedin.com/in/heatherraemartin/" rel="nofollow" target="_blank">Heather Martin</a> discuss the results of their analysis, what developers can expect from payers in launch year, and how they can prepare the best possible access outcome for their new drug.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at <a href="http://www.insightshub.health" rel="nofollow" target="_blank">insightshub.health</a>.Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Denials, Delays and Deep Discounts in Pharmaceutical Launch

According to Leigh Householder, Managing Director of Innovation for inVentiv Health Communications, in an industry where the appetite for innovation and change is strong, but the tolerance for risk is not, the answer lies in an accountable, data-driven marketing approach that allows for "targeted innovation” and leads to measurable impact.   inVentiv Health Podcast host Jeff Stewart talks with Leigh about the value of predictive analytics in endlessly experimenting with channels and messages without spending a single dollar on in-market pilots. They’ll also discuss why the 70/20/10 approach to planning is important -- including how it worked for the BBC -- and the potential impact of the millennial physician on pharma’s marketing decisions.  Have a listen to hear the latest in truly innovative customer and physician engagement tools and technologies that hint at the future of pharma communications.   The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.  The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you.  inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.   The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health’s clients, customers or other contacts. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

According to Leigh Householder, Managing Director of Innovation for inVentiv Health Communications, in an industry where the appetite for innovation and change is strong, but the tolerance for risk is not, the answer lies in an accountable, <a href="https://www.datadrivenexpectations.com/#download-report" rel="nofollow" target="_blank">data-driven marketing</a> approach that allows for "targeted innovation” and leads to measurable impact. inVentiv Health Podcast host Jeff Stewart talks with Leigh about the value of <a href="http://inventivhealthcommunications.com/how-we-think/reports/freedom-to-fail.html" rel="nofollow" target="_blank">predictive analytics</a> in endlessly experimenting with channels and messages without spending a single dollar on in-market pilots. They’ll also discuss why the 70/20/10 approach to planning is important -- including how it worked for the BBC -- and the potential impact of the <a href="https://inventivhealth-pr.com/perspectives/millennial-mindset" rel="nofollow" target="_blank">millennial physician</a> on pharma’s marketing decisions. Have a listen to hear the latest in <a href="http://www.healthexperienceproject.com/" rel="nofollow" target="_blank">truly innovative customer and physician engagement tools</a> and technologies that hint at the future of pharma communications. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health’s clients, customers or other contacts. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 004: Innovation in Pharma Communications

As we learned in our previous episode, naming a company is not something you can do by just “winging it.” The same holds true when it comes to naming a drug – especially in a podcast episode under 30 minutes. In Part 2 of our naming series, Addison Whitney Creative Director Brittany Scott explains the ins and outs of drug naming, addresses a possible conspiracy theory and runs host Jeff Stewart through the process in a quick (and frustrating) game of “Name That Drug.”  See our full list of podcast episodes here.    The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.  The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

As we learned in our <a href="http://www.buzzsprout.com/85116/621180-episode-010-naming-part-1-the-pharma-company" rel="nofollow" target="_blank">previous episode</a>, naming a company is not something you can do by just “winging it.” The same holds true when it comes to naming a drug – especially in a podcast episode under 30 minutes. In Part 2 of our naming series, <a href="http://addisonwhitney.com/" rel="nofollow" target="_blank">Addison Whitney</a> Creative Director <a href="https://www.linkedin.com/in/brittany-scott-b22417a/" rel="nofollow" target="_blank">Brittany Scott</a> explains the ins and outs of drug naming, addresses a possible conspiracy theory and runs host Jeff Stewart through the process in a quick (and frustrating) game of “Name That Drug.” See our full list of podcast episodes <a href="http://www.buzzsprout.com/85116" rel="nofollow" target="_blank">here</a>. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you. Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 011: Naming, Part 2 - The Drug

The patient standing at the pharmacy to fill a prescription represents the "final mile" that started in the laboratory. All the science and commercial investment comes down to this one decision point. Will the patient walk away? What will get them to stay? In a survey of 200,000 retail prescriptions for the top 100 branded oral drugs, two inVentiv companies - Adheris Health and inVentiv Health Consulting - set out to understand the most influential factors to driving patient adherence or non-adherence. Jeff Stewart sits down with Linda Morini, Senior Director, Analytic Services and Mike Occhipinti, Vice President, Analytics at Adheris Health, to discuss what they found. Interested in learning more about the complex issue of adherence? Check out the inVentiv Health Communications white paper on social centricity, which discusses social forces that shape patient decisions. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

The patient standing at the pharmacy to fill a prescription represents the "final mile" that started in the laboratory. All the science and commercial investment comes down to this one decision point. Will the patient walk away? What will get them to stay? In a survey of 200,000 retail prescriptions for the top 100 branded oral drugs, two inVentiv companies - Adheris Health and inVentiv Health Consulting - set out to understand the most influential factors to driving patient adherence or non-adherence. Jeff Stewart sits down with Linda Morini, Senior Director, Analytic Services and Mike Occhipinti, Vice President, Analytics at Adheris Health, to discuss what they found. Interested in learning more about the complex issue of adherence? Check out the inVentiv Health Communications <a href="http://inventivhealthcommunications.com/how-we-think/blogs/report/advancing-beyond-patient-centricity-identifying-the-reallife-influences-of-health-behavior-using-a-socialcentric-approach.html" rel="nofollow" target="_blank">white paper on social centricity</a>, which discusses social forces that shape patient decisions. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you. inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 006: Crossing the Finish Line: Factors Driving Patient Adherence to Drug Therapy

Since Stanley Kubrick's 2001: A Space Odyssey introduced the prospect of Artificial Intelligence (AI) with the spaceship computer system HAL, the world has had a rollercoaster relationship with the idea - from hope to hype, and everywhere in between. Have we "unleashed the demon" with AI, or does the potential of deep learning and machine learning for improving health outcomes far outweigh the fear factor? Duncan Arbour, Senior Vice President, Innovation with Syneos Health Communications, takes us on a fascinating journey through the progression of AI, its application in healthcare and touching on its potential impact on biopharma companies, healthcare providers, investors and the industry as a whole. But what about the perspective of the patient - up till now, the missing component in healthcare's AI conversation? To answer this question, Arbour shares the findings from a new Syneos Health report, Artificial Intelligence for Authentic Engagement: Patient Perspectives on Healthcare's Evolving AI Conversation, based on a survey of 800 patients regarding their expectations and concerns around the potential role of AI in diagnosis, treatment and support in their day-to-day lives. Also referenced in this episode:  The Gartner Hype Cycle Google alum Sebastian Thrun's paper on melanoma diagnosis through machine learning in the journal Nature Geoffrey Hinton's comparison of radiologists to Wile E. Coyote IBM supercomputer Watson versus cancer The General Data Protection Regulation in the EU Investment opportunity for AI in the healthcare sector The "Speak Easy" study on the potential for voice assistance to build relationships The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Since Stanley Kubrick's 2001: A Space Odyssey introduced the prospect of Artificial Intelligence (AI) with the spaceship computer system HAL, the world has had a rollercoaster relationship with the idea - from hope to hype, and everywhere in between. Have we "unleashed the demon" with AI, or does the potential of deep learning and machine learning for improving health outcomes far outweigh the fear factor? <a href="https://www.linkedin.com/in/duncanarbour/" rel="nofollow" target="_blank">Duncan Arbour</a>, Senior Vice President, Innovation with <a href="http://syneoshealthcommunications.com/" rel="nofollow" target="_blank">Syneos Health Communications</a>, takes us on a fascinating journey through the progression of AI, its application in healthcare and touching on its potential impact on biopharma companies, healthcare providers, investors and the industry as a whole. But what about the perspective of the patient - up till now, the missing component in healthcare's AI conversation? To answer this question, Arbour shares the findings from a new Syneos Health report, <a href="http://syneoshealthcommunications.com/perspectives/artificial-intelligence-for-authentic-engagement" rel="nofollow" target="_blank">Artificial Intelligence for Authentic Engagement: Patient Perspectives on Healthcare's Evolving AI Conversation</a>, based on a survey of 800 patients regarding their expectations and concerns around the potential role of AI in diagnosis, treatment and support in their day-to-day lives. Also referenced in this episode: <ul> <li>The <a href="https://www.gartner.com/technology/research/methodologies/hype-cycle.jsp" rel="nofollow" target="_blank">Gartner Hype Cycle</a></li> <li>Google alum Sebastian Thrun's paper on melanoma diagnosis through machine learning in the journal <a href="https://www.nature.com/articles/nature21056" rel="nofollow" target="_blank">Nature</a></li> <li>Geoffrey Hinton's <a href="https://chatbotslife.com/a-coyote-that-ran-over-the-edge-differing-opinions-about-the-impact-of-ai-on-radiology-4b5e3860722e" rel="nofollow" target="_blank">comparison of radiologists to Wile E. Coyote</a></li> <li>IBM supercomputer <a href="https://www.statnews.com/2017/09/05/watson-ibm-cancer/" rel="nofollow" target="_blank">Watson versus cancer</a></li> <li>The <a href="https://www.privacy-regulation.eu/en/article-22-automated-individual-decision-making-including-profiling-GDPR.htm" rel="nofollow" target="_blank">General Data Protection Regulation</a> in the EU</li> <li><a href="https://www.cbinsights.com/research/healthcare-ai-startup-boom-expert-research/" rel="nofollow" target="_blank">Investment opportunity</a> for AI in the healthcare sector</li> <li>The <a href="http://www.businessinsider.com/jwt-speak-easy-study-people-fantasised-about-alexa-2017-4" rel="nofollow" target="_blank">"Speak Easy" study</a> on the potential for voice assistance to build relationships</li> <li><a href="https://www.theatlantic.com/business/archive/2018/01/amazon-berkshire-jpmorgan-health-care/551858/" rel="nofollow" target="_blank"></a></li></ul>The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 013: Artificial Intelligence for Authentic Engagement

Channels of influence in pharma have expanded from the traditional offline sphere of publications, trials, conference activities and others to include a vast new digital landscape that is shaping the way we need to interact with a new generation of key opinion leaders -- so-called "digital" KOLs. Digital KOLs have an "omnipresent" digital footprint that can include social media, independent websites, healthcare professional discussion platforms like SERMO and Doximity and a seemingly endless number of other potential channels. So what does this mean for those trying to find and reach out to these key influencers?  Nick Lapolla, Manager, KOL Market Research at inVentiv Health Research and Insights and Madeline Rounds, Consultant on the inVentiv Health Medical Communications team, discuss how KOL mapping in this new age is both easier and harder than it used to be, highlight best practices and tactics and explain why it's still necessary to keep a human element in the mix. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timelThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com. 

Channels of influence in pharma have expanded from the traditional offline sphere of publications, trials, conference activities and others to include a vast new digital landscape that is shaping the way we need to interact with a new generation of key opinion leaders -- so-called "digital" KOLs. Digital KOLs have an "omnipresent" digital footprint that can include social media, independent websites, healthcare professional discussion platforms like <a href="http://www.sermo.com/" rel="nofollow" target="_blank">SERMO</a> and <a href="https://www.doximity.com/" rel="nofollow" target="_blank">Doximity</a> and a seemingly endless number of other potential channels. So what does this mean for those trying to find and reach out to these key influencers? Nick Lapolla, Manager, KOL Market Research at <a href="http://www.encuity.com/index.cfm" rel="nofollow" target="_blank">inVentiv Health Research and Insights</a> and Madeline Rounds, Consultant on the <a href="http://inventivmedcomms.com/" rel="nofollow" target="_blank">inVentiv Health Medical Communications</a> team, discuss how KOL mapping in this new age is both easier and harder than it used to be, highlight best practices and tactics and explain why it's still necessary to keep a human element in the mix. The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter. The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timelThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">Syneos Health Insights Hub</a>. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at <a href="https://www.syneoshealth.com/insights-hub" rel="nofollow" target="_blank">insightshub.health</a>. Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at <a href="mailto:podcast@syneoshealth.com">podcast@syneoshealth.com</a>.

Episode 007: Medicine in 140 Characters: Digital KOLs

The best episodes for anyone looking to learn more about topics such as happiness, fulfillment, depression and psychology/mental health in general. With interviews with industry experts, personal stories of individuals, this topic has lessons applicable to everyone. Add episodes you're interested into your queue below!

Best Episodes on Mental Health, Emotions & Thoughts

The best podcast episodes on Startups. For anyone working in a startup, or anyone interested in the incredible stories behind how people built companies like Instagram, and Facebook. Offering both practical advice and insights, as well as the stories for how many of the biggest startups got to where they are today. Add episodes you're interested into your queue below!